Abstract: The present disclosure provides methods for treating multiple myeloma that comprise administering isatuximab to the individual at a dose of 10 mg/kg on Days 1, 8, 15, and 22 of a first 28-day cycle; administering the isatuximab at a dose of 10 mg/kg on Days 1 and 15 of a 28-day cycle, e.g., for at least 11 cycles, or e.g., until the individual achieves or is determined to achieve at least Very Good Partial Response (VGPR) to treatment; and administering the isatuximab at a dose of 10 mg/kg once every 28 days of one or more additional 28-day cycles.

Abstract: The present invention relates to the compound having the following formula (I): which may be in base form or in the form of a hydrate or a solvate, for its use as a medicament in the treatment of cancer in patients with hepatic impairment.